A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.

Journal: Ophthalmology science
Published Date: Dec 12, 2023

Abstract

OBJECTIVE: Dry eye disease (DED) is a worldwide source of ocular discomfort. This first-in-human phase 2 clinical study determined the efficacy of treating signs and symptoms of DED using an ophthalmic solution of synthesized mimetic of human collagen (ST-100).

Authors

  • Robert O Baratta
    Stuart Therapeutics, Inc., Stuart, Florida.
  • Eric Schlumpf
    Stuart Therapeutics, Inc., Stuart, Florida.
  • Brian J Del Buono
    Stuart Therapeutics, Inc., Stuart, Florida.
  • Shawn DeLorey
    Stuart Therapeutics, Inc., Stuart, Florida.
  • George Ousler
    Ora Clinical, Inc., North Andover, Massachusetts.
  • David J Calkins
    Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals